Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov ID: NCT00950807

Public ClinicalTrials.gov record NCT00950807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.

Study identification

NCT ID
NCT00950807
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
176 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Feb 28, 2010
Completion
Mar 14, 2010
Last update posted
Nov 7, 2017

2009 – 2010

United States locations

U.S. sites
10
U.S. states
4
U.S. cities
10
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85013
GSK Investigational Site San Diego California 92117
GSK Investigational Site Upland California 91786
GSK Investigational Site Cincinnati Ohio 45231
GSK Investigational Site Easley South Carolina 29640
GSK Investigational Site Gaffney South Carolina 29340
GSK Investigational Site Greenville South Carolina 29615
GSK Investigational Site Seneca South Carolina 29678
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00950807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00950807 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →